Earlier this year, the US FDA approved Kalydeco for eight additional mutations (G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P or G1349D), adding another 400-or-so patients to the drug's ...
Launched in 2012, Vertex's Kalydeco has been a breakthrough in treating cystic fibrosis, being the first drug to target defective proteins which lead to damaging chest infections.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback